We have located links that may give you full text access.
Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
Journal of the Association of Physicians of India 2018 December
This brief communication describes evidence which proves the beneficial effects of fenofibrate on the retinal vasculature in type 2 diabetes, acting via both lipid lowering and non-lipid lowering mechanisms. It discusses data from FIELD and other trials to support the use of fenofibrate as a secondary preventive therapy for diabetic retinopathy. These data contrast with the lack of retinal benefit shown in major cardiovascular outcome trials of other blood pressure lowering and glucose lowering agents such as empagliflozin, liraglutide, perindopril + indapamide, and ramipril.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app